Insmed (NASDAQ:INSM) Reaches New 12-Month High – Should You Buy?

Insmed, Inc. (NASDAQ:INSM)’s stock price hit a new 52-week high on Friday . The company traded as high as $197.45 and last traded at $196.03, with a volume of 1060829 shares changing hands. The stock had previously closed at $190.96.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the stock. Truist Financial raised their target price on shares of Insmed from $126.00 to $139.00 and gave the stock a “buy” rating in a report on Thursday, August 14th. Bank of America upped their price objective on Insmed from $142.00 to $187.00 and gave the stock a “buy” rating in a research note on Monday, October 27th. TD Cowen raised their target price on Insmed from $154.00 to $193.00 and gave the company a “buy” rating in a research note on Thursday, October 2nd. Cantor Fitzgerald assumed coverage on shares of Insmed in a research report on Tuesday, October 28th. They set an “overweight” rating and a $192.00 price target for the company. Finally, Mizuho set a $196.00 price objective on shares of Insmed in a report on Wednesday, October 29th. Nineteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $173.29.

Insmed Price Performance

The company has a quick ratio of 6.33, a current ratio of 6.68 and a debt-to-equity ratio of 0.45. The company has a 50 day moving average of $161.39 and a two-hundred day moving average of $119.49. The firm has a market cap of $41.75 billion, a P/E ratio of -34.24 and a beta of 1.05.

Insmed (NASDAQ:INSM) last posted its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported ($1.75) earnings per share for the quarter, missing the consensus estimate of ($1.35) by ($0.40). Insmed had a negative net margin of 259.82% and a negative return on equity of 195.37%. The business had revenue of $142.34 million for the quarter, compared to the consensus estimate of $114.33 million. During the same quarter last year, the business posted ($1.27) EPS. The business’s revenue for the quarter was up 52.4% on a year-over-year basis. Insmed has set its FY 2025 guidance at EPS. Sell-side analysts expect that Insmed, Inc. will post -4.56 EPS for the current year.

Insider Activity at Insmed

In related news, COO Roger Adsett sold 25,000 shares of Insmed stock in a transaction on Tuesday, August 19th. The stock was sold at an average price of $127.58, for a total value of $3,189,500.00. Following the transaction, the chief operating officer directly owned 105,637 shares in the company, valued at $13,477,168.46. The trade was a 19.14% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Michael Alexander Smith sold 27,130 shares of the company’s stock in a transaction on Monday, November 3rd. The shares were sold at an average price of $183.78, for a total value of $4,985,951.40. Following the sale, the insider directly owned 54,902 shares of the company’s stock, valued at approximately $10,089,889.56. This represents a 33.07% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 179,787 shares of company stock worth $26,428,149. 3.00% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in INSM. M&T Bank Corp grew its position in Insmed by 4.7% during the 1st quarter. M&T Bank Corp now owns 3,293 shares of the biopharmaceutical company’s stock worth $252,000 after purchasing an additional 147 shares in the last quarter. Nisa Investment Advisors LLC lifted its stake in Insmed by 6.5% in the 1st quarter. Nisa Investment Advisors LLC now owns 3,761 shares of the biopharmaceutical company’s stock worth $287,000 after acquiring an additional 228 shares in the last quarter. Cerity Partners LLC boosted its position in Insmed by 72.2% during the 1st quarter. Cerity Partners LLC now owns 31,438 shares of the biopharmaceutical company’s stock worth $2,398,000 after acquiring an additional 13,180 shares during the period. Xponance Inc. boosted its position in Insmed by 5.3% during the 1st quarter. Xponance Inc. now owns 13,359 shares of the biopharmaceutical company’s stock worth $1,019,000 after acquiring an additional 670 shares during the period. Finally, Mutual of America Capital Management LLC grew its stake in Insmed by 2.7% during the 1st quarter. Mutual of America Capital Management LLC now owns 79,141 shares of the biopharmaceutical company’s stock valued at $6,038,000 after acquiring an additional 2,093 shares in the last quarter.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.